Loncastuximab tesirine (Zynlonta®). HTA ID: 23053

Assessment Status Rapid Review Complete
HTA ID 23053
Drug Loncastuximab tesirine
Brand Zynlonta®
Indication Loncastuximab tesirine (Zynlonta®) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
Assessment Process
Rapid review commissioned 17/08/2023
Rapid review completed 01/09/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of loncastuximab tesirine compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.